Z. E. Afridonova

Z. E. Afridonova

Auto-generated profile, based on publicly available information

Z. E. Afridonova

G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology, Federal Service for Supervision on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), Moscow

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2025 in Russian Journal of Immunology
Verified
Journal Article
Open access
PDF file
ZAZ. E. Afridonova
Z. E. Afridonova
ATAnna P. Toptygina
Anna P. Toptygina
ESElena L. Semikina
Elena L. Semikina
Ending of COVID-19 pandemic does not exclude subsequent breakthrough infections caused by SARS-CoV-2 mutant strains. The rate of SARS-CoV-2 mutations increased with emerging omicron strain and exceeds those of the influenza virus. It remains unclear what IgG antibody levels are able to protect against new mutant SARS-CoV-2 strains, and how long the immune protection will last. The objective of this study was to monitor the maintenance of humoral and cellular immunity to SARS-CoV-2 viral antigens over 4 years after the infection. Thirty-two adult reconvalescents after COVID-19 were annually examined for humoral and cellular immunity markers to the SARS-CoV-2 S protein. Humoral immunity was assessed by ELISA; cellular immunity was evaluated by expression of CD107a on CD8hi lymphocytes after recognition of S protein antigens. A four-year observation of a group of patients who recovered from COVID-19 in 2020 (SARS-CoV-2, Wuhan strain) and were in contact with a novel, freely circulating mutant VoCs showed that, 1 year later, all subjects retained the IgG antibodies to S protein, mainly the IgG1 subclass, but the antibody avidity index barely exceeded 50%. After a breakthrough infection caused by the omicron strain, the level of IgG antibodies to S protein increased significantly, along with sufficient increase of antibody avidity. The IgG2, IgG3, and IgG4 antibodies to S protein occured in the spectrum of subclasses. The level of specific IgA decreased 1 year after the disease against their level after the primary disease. However, it was significantly increased to 4-5 PR after breakthrough infections. Cellular immunity to the SARS-CoV-2 S protein was detected in all subjects at 1 year after the primary disease. After repeated infection with the omicron strain, it increased significantly and remained at this level for the next year. By 4 years, it decreased to the level that was a year after the disease. Hence, humoral and cellular immunity to S protein does not fade away, but continues to persist, maturate, being maintained at a sufficient level. Upon exposure to a new VoC, it allows to endure such a meeting either asymptomatically, or as a mild clinical infection. In view of frequent mutations in the S protein, the role of T-cell responses in anti-infectious protection seems to increase significantly. When developing new vaccines, one should rely on development of cellular immunity.

1 January 2026 in Immunologiya
Verified
Journal Article
Closed access
ATA.P. Toptygina
A.P. Toptygina
ZAZ.E. Afridonova
Z.E. Afridonova
PZP.E. Zherdeva
P.E. Zherdeva
OGO.G. Grechishnikova
O.G. Grechishnikova
MSM.A. Smerdova
M.A. Smerdova